CLT Research & Evidence Base 2 — Questions and Answers
Question 1: Which assessment tool was specifically developed to measure insight in individuals with schizophrenia and is commonly used in LEAP-related research?
- Beck Cognitive Insight Scale
- Scale to Assess Unawareness of Mental Disorder (SUMD) (Correct answer)
- Positive and Negative Syndrome Scale
- Calgary Depression Scale
Correct answer: Scale to Assess Unawareness of Mental Disorder (SUMD)
The SUMD (Scale to Assess Unawareness of Mental Disorder), developed by Amador and colleagues, directly measures anosognosia across symptom domains in schizophrenia research.
Question 2: Research on anosognosia prevalence in schizophrenia consistently shows that what approximate percentage of individuals have significant unawareness of their illness?
- 10–15%
- 20–30%
- 40–50% (Correct answer)
- 70–80%
Correct answer: 40–50%
Studies estimate that approximately 40–50% of people with schizophrenia have significant anosognosia, making it one of the most common features of the illness.
Question 3: A study comparing LEAP-trained clinicians versus treatment-as-usual showed the greatest measurable difference in which outcome?
- Symptom severity reduction
- Medication adherence rates (Correct answer)
- Inpatient hospitalization length
- Cognitive functioning scores
Correct answer: Medication adherence rates
LEAP research consistently demonstrates its strongest effect on medication adherence, as the approach directly targets the therapeutic alliance barrier posed by poor insight.
Question 4: The concept of 'reflective listening' in LEAP's evidence base draws most heavily from the randomized controlled trial literature of which parent approach?
- Cognitive Behavioral Therapy
- Motivational Interviewing (Correct answer)
- Dialectical Behavior Therapy
- Acceptance and Commitment Therapy
Correct answer: Motivational Interviewing
Reflective listening in LEAP is grounded in Motivational Interviewing (MI), whose RCT evidence base in substance use and health behavior change directly informed LEAP's development.
Question 5: In neuroimaging studies referenced in anosognosia research, poor illness insight is most consistently associated with dysfunction in which brain region?
- Occipital lobe
- Cerebellum
- Prefrontal cortex and anterior cingulate (Correct answer)
- Brainstem reticular formation
Correct answer: Prefrontal cortex and anterior cingulate
Neuroimaging research links anosognosia to prefrontal cortex and anterior cingulate dysfunction, impairing self-monitoring and error-detection capacities.
Question 6: Which research design is considered the gold standard for evaluating LEAP's efficacy in improving treatment engagement?
- Cross-sectional survey
- Case series report
- Randomized controlled trial with blinded outcome assessment (Correct answer)
- Retrospective chart review
Correct answer: Randomized controlled trial with blinded outcome assessment
Randomized controlled trials with blinded outcome assessment provide the highest level of evidence for causal claims about LEAP's efficacy.
Question 7: Early studies on insight deficits in psychosis found that poor insight was a stronger predictor of medication nonadherence than which competing factor?
- Side effect burden (Correct answer)
- Socioeconomic status
- Duration of untreated psychosis
- Family support level
Correct answer: Side effect burden
Research demonstrated that insight deficit predicted nonadherence more powerfully than side effect burden, challenging the assumption that medication problems alone drove noncompliance.
CLT Research & Evidence Base 2
Which assessment tool was specifically developed to measure insight in individuals with schizophrenia and is commonly used in LEAP-related research?